Clopidogrel and Proton Pump Inhibitors: Is There a Significant Drug-Drug Interaction?

Shmulevich, Emilia; Friger, Michael; Gilutz, Harel; Azab, Abed N.
October 2011
Canadian Journal of Cardiovascular Nursing;2011, Vol. 21 Issue 4, p27
Academic Journal
Dual antiplatelet therapy with aspirin and clopidogrel is among the most efficacious treatment for patients after acute coronary syndromes and for those who have had a percutaneous coronary intervention and coronary stent implantation. Patients who are treated with dual antiplatelet therapy are usually also ordered medications that reduce the secretion of gastric acid (such as H2 receptor blockers or proton pump inhibitors [PPIs]) in order to decrease the risk of gastrointestinal bleeding and dyspepsia. Numerous observational studies reported that omeprazole (a PPI) attenuates the antiplatelet activity and clinical effectiveness of clopidogrel and causes adverse cardiovascular events. Based on these findings, several medical agencies in the world have issued communications regarding the negative interaction between clopidogrel and PPIs, urging clinicians to evaluate the need for starting treatment with a PPI in patients taking clopidogrel. There are studies that reported contradicting findings, suggesting that there is no significant interaction between clopidogrel and PPIs. Only one prospective, randomized, double-blind, placebo-controlled clinical trial examined the interaction between clopidogrel and omeprazole and did not demonstrate cardiovascular harm among the patients who were treated with clopidogrel and omeprazole, as compared to those who were treated with clopidogrel and placebo. In this article, the authors review the current studies that reported a possible drug-drug interaction between clopidogrel and PPIs, particularly omeprazole.


Related Articles

  • Interaction Between Clopidogrel and Proton Pump Inhibitors: Hypothesis to Explain Multifactorial CYP2C19 Inhibition. Huixia Zhang; Ragueneau-Majlessi, Isabelle; Levy, Rene H. // Drug Metabolism Letters;Dec2009, Vol. 3 Issue 4, p287 

    Clopidogrel is an antiplatelet drug that requires bioactivation to its active metabolite to demonstrate its antiplatelet effect. Formation of the active metabolite involves multiple cytochrome P450 enzymes, with CYP2C19 playing an important role. Clopidogrel is often co-administered with proton...

  • PPIs and Clopidogreh Do We Have to Worry? Kuritzky, Louis // Infectious Disease Alert;Dec2009 Clinical Briefs in Primary, p1 

    The article discusses research on the interaction between proton pump inhibitors (PPI) and clopidogrel. It references a study by M. L. O'Donoghue and colleagues, published in the 2009 issue of "Lancet." The study found that patients who are taking clopidogrel and PPI have reduced platelet...

  • Interaction of Proton pump inhibitor and Clopidogrel- A Lurch. Praveen, R. // Journal of Pharmacy Research;Aug2010, Vol. 3 Issue 8, p1971 

    Clopidogrel belong to a thienopyridine antiplatelet drug, which is most commonly prescribed in the treatment of Acute Coronary Syndrome (ACS), stroke and later on given as a prophylactic treatment. Aspirin an acetyl salicylic acid is also co prescribed along with clopidogrel to have an...

  • Experts OK Antiplatelets and PPIs for Heart Patients With GI Bleeding Risks. Voelker, Rebecca // JAMA: Journal of the American Medical Association;1/12/2011, Vol. 305 Issue 2, p135 

    The article focuses on a consensus document released by the American College of Cardiology Foundation, the American College of Gastroenterology and the American Heart Association which approved the concomitant use of antiplatelet drugs and proton pump inhibitors (PPIs) in patients who are at...

  • Antiplatelets and PPIs top sellers in first quarter 2012.  // PharmacoEconomics & Outcomes News;8/4/2012, Issue 659, p11 

    The article reports on the increase in sales of antiplatelet agent clopidogrel and proton pump inhibitor esomeprazole in the U.S. during the first quarter of 2012.

  • Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Ogawa, Ryuichi; Echizen, Hirotoshi // Clinical Pharmacokinetics;2010, Vol. 49 Issue 8, p509 

    Proton pump inhibitors (PPIs) are widely prescribed for the treatment of gastric acid-related disorders and the eradication of Helicobacter pylori. In addition, they are routinely prescribed for the prevention of gastrointestinal bleeding in patients receiving a dual antiplatelet therapy...

  • Omeprazole and Clopidogrel -- Is There a Clinically Meaningful Interaction? Boyle, Andrew J. // Clinical Oncology Alert;Jan2011, Vol. 27 Issue 1, p4 

    The article highlights a placebo-controlled trial by Bhatt and colleagues to determine a clinical interaction between Omeprazole that reduces the risk of Gastrointestinal (GI) bleeding in patients on dual anti-platelet therapy (DAPT) and Clopidogrel. It is inferred that there was no apparent...

  • Drug-Drug Interactions Associated with Antiplatelet Therapy. Dunn, Steven P.; Macaulay, Tracy E. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2011, Vol. 9 Issue 4, p231 

    Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are...

  • Entfernung eines Periduralkatheters unter dualer Antiplättchentherapie nach akutem Koronarsyndrom. Limper, U.; Lynch, J. // Anaesthesist;Aug2012, Vol. 61 Issue 8, p686 

    This article reports the case of a patient who developed acute coronary syndrome while receiving postoperative pain treatment via an epidural catheter (EC). Platelet function testing was performed before removal of the EC to assess the bleeding risk under ongoing dual antiplatelet therapy....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics